Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions: 0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 110 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Trauma, Trauma Injury, Pain, Acute
Interventions: Bupivacaine Liposome Injection, Bupivacaine; Drug
Lead sponsor: Chadrick Evans; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Alopecia Areata
Interventions: MedJet Device with intralesional triamcinolone; Combination Product
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Skin Quality
Interventions: Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution; Drug · Other
Lead sponsor: Steve Yoelin M.D. Medical Associates, Inc.; Other
Eligibility: 35 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions: Suboxone, Truvada, Mavyret; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Greensboro, North Carolina

Conditions: Healthy Volunteers
Interventions: Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sunscreen
Interventions: Sunscreen A, Sunscreen B, Sunscreen C, Sunscreen D, Sunscreen E, Sunscreen F; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Brassiere Strap Fat (BSF), Bra Strap Fat (BSF)
Interventions: Deoxycholic Acid; Drug
Lead sponsor: Juva Skin & Laser Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Lower Extremity Chronic Ulcers in Diabetics
Interventions: CureXcell®, Sham injection; Biological
Lead sponsor: Macrocure Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 31
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more

Conditions: Hypereosinophilic Syndrome
Interventions: dupilumab; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epidural Placement
Interventions: BrightPoint; Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteer
Interventions: Lebrikizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Macular Edema, Diabetic
Interventions: Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more

Conditions: Obesity, Overweight
Interventions: NNC0113-5840, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Knee Injury
Interventions: J-Tip, Syringe and 25 gauge needle; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 119
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more

Conditions: Sunscreen
Interventions: Sunscreen A, Sunscreen B, Sunscreen C; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS); Biological · Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more

Conditions: Asthma
Interventions: IM epinephrine 1:1000, No intervention; Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 6 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: HPV Seroconversion
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Evaluation of Skin Quality Improvement

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the "Bra Strap Fat" Region

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

BrightPoint Reflectometer Device Study

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

COMbination of Bipolar Androgen Therapy and Nivolumab

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones

Effects of Aging on Primary and Secondary Vaccine Responses

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation

Gardasil Immunogenicity With Needle-Free Injection